New pill could slow blindness in inherited eye disease
NCT ID NCT07408232
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new oral drug called OCT-980 for people with a specific inherited eye disease (autosomal dominant retinitis pigmentosa) that causes gradual vision loss and blindness. The study first gives a single dose to healthy volunteers to check safety, then multiple doses to patients. The goal is to see if the drug is safe and can slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OCT-980 (oral capsule or tablet)
What this could lead to
If successful, this could point toward a treatment that slows or stops vision loss in people with a specific genetic form of retinitis pigmentosa.
What could go wrong
This is a very early, first-in-human trial with only 32 participants. The drug may not be safe or effective, and results may not apply to other forms of retinitis pigmentosa.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia